21
views
0
recommends
+1 Recommend
1 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: not found

      The MERS-CoV receptor DPP4 as a candidate binding target of the SARS-CoV-2 spike

      research-article

      Read this article at

      ScienceOpenPublisherPMC
      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          SUMMARY

          The ongoing outbreak of the novel coronavirus pneumonia COVID-19 has caused great number of cases and deaths, but our understanding about the pathogen SARS-CoV-2 remains largely unclear. The attachment of the virus with the cell-surface receptor and a co-factor is the first step for the infection. Here, bioinformatics approaches combining human-virus protein interaction prediction and protein docking based on crystal structures have revealed the high affinity between human dipeptidyl peptidase 4 (DPP4) and the spike (S) receptor-binding domain of SARS-CoV-2. Intriguingly, the crucial binding residues of DPP4 are identical to those as bound to the MERS-CoV-S. Moreover, E484 insertion and adjacent substitutions should be most essential for this DPP4-binding ability acquirement of SARS-CoV-2-S compared with SARS-CoV-S. This potential utilization of DPP4 as a binding target for SARS-CoV-2 may offer novel insight into the viral pathogenesis, and help the surveillance and therapeutics strategy for meeting the challenge of COVID-19.

          Graphical Abstract

          Highlights

          • SARS-CoV-2 spike receptor-binding domain has a potentially high affinity with DPP4

          • SARS-CoV-2-S/DPP4 binding shares key DPP4 residues with that of MERS-CoV-S/DPP4

          • E484 and adjacent mutations are critical for the DPP4-binding ability of SARS-CoV-2-S

          Related collections

          Author and article information

          Contributors
          Journal
          iScience
          iScience
          iScience
          The Author(s).
          2589-0042
          13 May 2020
          13 May 2020
          : 101160
          Affiliations
          [1 ]Department of Hematology, Xiangya Hospital, Central South University, Changsha 410080, China
          [2 ]State Key Laboratory of Agrobiotechnology, College of Biological Sciences, China Agricultural University, Beijing 100193, China
          [3 ]Department of Microbiology, School of Basic Medical Science, Central South University, Changsha 410078, China
          [4 ]China-Africa Research Center of Infectious Diseases Central South University, Changsha 410013, China
          Author notes
          []Corresponding author jianhlu@ 123456csu.edu.cn
          [5]

          These authors contributed equally.

          [6]

          Lead Contact

          Article
          S2589-0042(20)30345-X 101160
          10.1016/j.isci.2020.101160
          7219414
          32405622
          c4019167-43d2-4727-ac47-19f860feb37d
          © 2020 The Author(s)

          Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.

          History
          : 30 March 2020
          : 28 April 2020
          : 11 May 2020
          Categories
          Article

          Comments

          Comment on this article